Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655071 | 0.88 | MAPT (0.36) | TBXAS1ALDH1A1LMNA | |
| SCHEMBL4654288 | 0.86 | TBXAS1 (0.32) | TBXAS1 | |
| SCHEMBL10858277 | 0.84 | TBXAS1 (0.36) | TBXAS1LMNA | |
| SCHEMBL10859530 | 0.78 | TBXAS1 (0.33) | TBXAS1 | |
| SCHEMBL4655093 | 0.75 | ALDH1A1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL4654001 | 0.74 | PIM1 (0.34) | TBXAS1LMNA | |
| SCHEMBL12431313 | 0.71 | HRH4 (0.34) | ALDH1A1 | |
| SCHEMBL10860124 | 0.71 | CYP2A6 (0.34) | ALDH1A1LMNA | |
| SCHEMBL4655217 | 0.70 | MEN1 (0.39) | TBXAS1 | |
| SCHEMBL18791453 | 0.68 | HRH4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | ABAT, BPTF, TNNT2 | TBXAS1 183/4885PNMT 1748/4885ALDH1A1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.